Eloctate
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Inhibitor formation is a serious complication of hemophilia A, occurring in up to 30% with severe disease. It is…
Introduction: Inhibitor formation affects approximately 30% of individuals with severe hemophilia A. The eradication of…
Eloctate, a recombinant factor VIII Fc fusion protein with an extended half-life, was effective in preventing and controlling…
Introduction: Current state of the art treatment of severe Hemophilia A is prophylactic or on-demand replacement of the deficient…
NEW DRUG APPROVALS Dalvance for Skin Infections The FDA has approved dalbavancin (Dalvance, Durata Therapeutics) to treat adults…